FSTX

F-Star Therapeutics Inc

A biopharmaceutical company that engineers "tetravalent bispecific" antibodies — immune-system proteins that grab two different targets at once — to treat cancer, with candidates aimed at checkpoints like PD-L1 and LAG-3. It was founded in 2006 in Vienna, Austria, and is now headquartered in Cambridge, UK. The name itself is a science joke of sorts: the "F" stands for the Fc region of the antibody, and "star" reflects how the platform adds new binding arms to create a star-like, multi-targeting shape.

No proxy statement recorded.